Morgans has published “Respiratory Franchise Builds” – its updated research on Invion Limited.
“IVX has a number of key milestones pending which include an update on the asthma trial with the NIH, a progress report on the inhaled program, interim data from the smoking cessation trial and completion of the analysis of the lupus data. These milestones are helping to build IVX’s respiratory franchise. We note continuing interest from big pharma in acquiring respiratory franchises. This week AstraZeneca has agreed to pay over an initial consideration of $US875m and up to US$1.2bn in other milestones for Almirall’s respiratory franchise…”